Fulcrum Therapeutics/FULC

$10.32

1.37%
-
1D1W1MYTD1YMAX

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). The Company has developed a product engine to identify and validate cellular drug targets that can modulate gene expression to treat known root causes of genetically defined diseases. The Company’s product engine integrates patient-derived tissue and disease-relevant cell models that it interrogates using its pharmacologically diverse and annotated small-molecule compound library and customized CRISPR and RNAi libraries.

Ticker

FULC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alex Sapir

Employees

89

Headquarters

Cambridge, United States

FULC Metrics

BasicAdvanced
$601.53M
Market cap
-
P/E ratio
-$1.69
EPS
2.29
Beta
-
Dividend rate

What the Analysts think about FULC

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
22.48% upside
High $19.00
Low $4.50
$10.32
Current price
$12.64
Average price target

FULC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,428.57% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$700K
-12.5%
Net income
$-24M
1.27%
Profit margin
-3,428.57%
15.73%

FULC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.04%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.41
-$0.38
-$0.39
-$0.40
-
Expected
-$0.46
-$0.44
-$0.44
-$0.43
-$0.44
Surprise
-9.99%
-14.52%
-10.34%
-6.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Fulcrum Therapeutics stock

Buy or sell Fulcrum Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing